Brawn Biotech
22.95
-22.95(-100.00%)
Market Cap₹6.90 Cr
PE Ratio31.40
IndustryHealthcare
Company Performance:
1D-100.00%
1M+9.29%
6M+11.79%
1Y+24.05%
5Y-15.93%
View Company Insightsright
More news about Brawn Biotech
29Dec 25
Brawn Biotech Ltd Director Resignation - Mrs. Brij Bala Gupta Steps Down
Brawn Biotech Limited has announced the resignation of Director Mrs. Brij Bala Gupta, effective November 25, 2025, due to pre-occupation and unavoidable circumstances. The company initially communicated this to BSE on December 22, 2025, but provided additional documentation on December 29, 2025, after acknowledging it had inadvertently omitted the resignation letter copy in its earlier communication.
 no imag found
14Nov 25
Brawn Biotech Reports Net Loss of Rs. 7.44 Lacs in Q2 FY2026
Brawn Biotech Limited announced its Q2 FY2026 results, reporting a net loss of Rs. 7.44 lacs despite revenue from operations increasing to Rs. 797.00 lacs. Total revenue rose to Rs. 806.12 lacs, up from Rs. 588.86 lacs in Q1 FY2026 and Rs. 355.73 lacs in Q2 FY2025. Total expenses increased to Rs. 798.98 lacs. The company's balance sheet shows total assets of Rs. 2,215.67 lacs and total equity of Rs. 370.52 lacs as of September 30, 2025. Auditors Rajiv Udai & Associates conducted a limited review, finding no issues with the financial results' presentation.
 no imag found
30Sept 25
Brawn Biotech Shareholders Approve Key Resolutions at 40th AGM
Brawn Biotech Limited held its 40th Annual General Meeting on September 30, 2025, via video conferencing. Shareholders approved several important resolutions including the re-appointment of Mr. Amit Kumar as Manager for a five-year term, adoption of a new Memorandum of Association, approval of financial statements, and re-appointment of Mrs. Brij Bala Gupta as director. All resolutions received overwhelming support with 99.99% votes in favor. The meeting, chaired by Mr. Brij Raj Gupta, lasted from 11:00 AM to 11:13 AM, with e-voting open for an additional 30 minutes.
 no imag found
13Aug 25
Brawn Biotech Reports Turnaround with Rs 23.60 Lacs Profit in Q1
Brawn Biotech Limited, a pharmaceutical company, has reported a significant turnaround in its Q1 financial performance. The company posted a profit of Rs 23.60 lacs, compared to losses in previous quarters. Revenue increased substantially to Rs 579.77 lacs, more than doubling from the previous quarter. The company's Earnings Per Share (EPS) improved to Rs 0.89. The statutory auditor conducted a limited review and found no issues with the financial results.
 no imag found
Brawn Biotech
22.95
-22.95
(-100.00%)
1 Year Returns:+24.05%
Industry Peers
Sun Pharmaceutical
1,618.50
(-0.12%)
Divis Laboratories
6,320.00
(-0.65%)
Torrent Pharmaceuticals
4,110.40
(-0.17%)
Dr Reddys Laboratories
1,313.00
(-0.31%)
Lupin
2,298.00
(+0.08%)
Cipla
1,296.00
(+0.08%)
Mankind Pharma
2,266.00
(-0.06%)
Zydus Life Science
926.95
(-0.05%)
Aurobindo Pharma
1,414.00
(+0.01%)
Glenmark Pharmaceuticals
2,287.00
(-0.54%)